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Abnormalities of essential fatty acid distribution in the plasma
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Summary We have examined the composition of the essential fatty acids in the plasma phospholipid fractions
of 98 patients with histologically proven bladder cancer. These patients were attending hospital for regular
follow-up by check cystoscopy. Patients were divided into two groups, depending on the cystoscopic findings,
of either active (tumour recurrence seen) or inactive (no evidence of tumour recurrence) disease. Compared
with a normal population, the plasma levels of most of the fatty acids, including arachidonic acid, were
significantly lower in the 98 cancer patients (P<0.001, t-test). We were unable, however, to demonstrate any
significant differences (Mann-Whitney U-test) between the active and inactive disease groups. Plasma levels of
the essential fatty acids are abnormal in patients with bladder cancer; they do not help, however, to distinguish
those patients with active disease from those with inactive disease. This may arise because the deficit in
essential fatty acids we have demonstrated is a predisposing factor for the development of bladder cancer
rather than a metabolic consequence of the tumour. Further studies are needed to establish the possible
clinical role of measurement of essential fatty acids in patients with bladder carcinoma.
While it is known that the composition of adipose tissue
reflects dietary fatty acid intake, the relationship between diet
and the plasma phospholipid composition may be relatively
weak (Horrobin et al., 1989; van Houwelingen et al., 1989).
These is remarkably little variation in plasma phospholipid
fatty acid composition among normal populations living in
widely different geographical locations. It has been suggested
that this relative constancy may make their measurement
useful in disease states (Horrobin et al., 1989).
Bladder cancer is a common neoplasm which affects three
times as n;any men as women and is a disease ofmiddle-aged
and elderly patients. The majority of these tumours are papil-
lary in type and can be managed using transurethral surgical
techniques. Many of these patients, however, will develop
recurrences of their neoplasms and hence require cystoscopic
follow-up examinations. We have measured the levels of the
essential fatty acids in the plasma phospholipids of patients
with bladder cancer to establish the possible role of these
measurements in clinical practice.
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Figure I Dietary fatty acid metabolic pathways.
Essentialfatty acid nomenclature
There are two families of essential fatty acids derived from
linoleic (18:2n6) and alpha-linolenic (18:3n3) acids. These
parent compounds undergo a process of elongation and
desaturation as outlined in Figure 1. Some of the subsequent
compounds are substrates for the eicosanoids - prostaglan-
dins, prostacyclin, thomboxanes and leukotrienes.
Materials and methods
Patients
Ninety-eight patients with a proven histological diagnosis of
bladder cancer, who were attending for regular check cysto-
scopy, had fasting blood samples taken before induction of
anaesthesia for cystoscopy. The fasting blood samples were
taken into EDTA-treated tubes, centrifuged at 800g for
5 min and the separated red cells and plasma frozen at
- 70°C until analysis.
Cystoscopic findings were recorded, and patients placed
into one of two groups, depending on the presence or
absence of recurrent disease. There were 55 patients with
active disease and 43 patients with no recurrence noted.
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EFA measurement
Plasma samples (1 ml) were extracted with chloroform:meth-
anol (2:1). The extract was filtered through sodium sulphate,
evaporated to dryness, and taken up in 0.5 ml chloroform:
methanol. The lipid fractions were separated by thin-layer
chromatography on silica gel plates. The phospholipid frac-
tion, which seems to reflect essential fatty acid changes most
sensitively, was methylated using boron trifulouride-methan-
ol. The resulting methyl esters of the fatty acids were
separated and measured using a Hewlett-Packard 5880 gas
chromatograph with a 6 foot column packed with 10% silar
on chromasorb WAW 106/230. The carrier gas was helium
(30 ml min '). Oven temperature was programmed to rise
from 165°C to 190°C at 2°C min-'. Detector temperature was
220°C and injector temperature 200°C. Retention times and
peak areas were automatically computed by a Hewlett-
Packard Level 4 integrator. Peaks were identified by com-
parison with standard fatty acid methyl esters from Nuchek
Prep. Inc., Elysian, Minnesota (USA). All figures are given as
a percentage of the total phospholipids.
The plasma levels of essential fatty acids used as controls
for this study were collected from 477 individuals in 15
different populations: four of these populations were from
the UK. (Horrobin et al., 1989). There is little variation in
these levels among normal populations so allowing their use
as controls for this study.
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Table I Age and sex distribution of patients with bladder cancer
Male Age Female Age All Age
(n) (Mean (s.d.)) (n) (Mean (s.d.)) (n) (Mean (s.d.))
Active 34 70 (7) 21 66 (9) 55 66 (11)
Inactive 32 67 (10) 11 67 (9) 43 67 (10)
All cases 66 69 (9) 32 67 (8) 98 67 (9)
Table II Fatty acid levels in plasma phospholipids of patients with bladder cancer
and a control population (figures expressed as percentage of total phospholipids -
Mean (s.d.))
Control All cancer Active Inactive
Fatty acid (n =477) (n=98) (n =55) (n =43)
16:0 26.9 (2.4)* 31.9 (3.7) 31.9 (3.5)ns 31.8 (3.9)
18:0 10.0 (2.9)t 10.8 (2.6) 10.6 (2.6)ns 11.1 (2.6)
18:1n9 13.4 (3.1)* 15.2 (2.3) 15.1 (2.4)ns 15.3 (2.1)
18:2n6 25.7 (4.0)* 23.2 (3.9) 23.4 (3.9)ns 22.9 (3.9)
20:3n6 2.6 (0.7)ns 2.6 (0.8) 2.7 (0.8)ns 2.5 (0.7)
20:4n6 11.0 (2.4)* 8.5 (1.5) 8.8 (1.6)ns 8.2 (1.4)
22:4n6 0.3 (0.2)* 0.1 (0.2) 0.1 (0.1)ns 0.1 (0.3)
22:5n6 0.2 (0.3)ns 0.1 (0.4) 0.1 (0.4)ns 0.2 (0.4)
18:3n3 0.2 (0.3)ns 0.1 (0.3) 0.1 (0.3)ns 0.2 (0.2)
20:5n3 1.4 (1.1)* 1.1 (0.8) 1.1 (0.8)ns 1.0 (0.7)
22:5n3 1.0 (0.3)* 0.5 (0.5) 0.4 (0.5)ns 0.6 (0.5)
22:6n3 4.6 (1.9)* 3.3 (1.8) 3.4 (1.9)ns 3.1 (1.6)
*P<0.001 (t-test); tP = 0.006 (t-test); ns - no significant difference
(Mann-Whitney or t-test)
Statistical analysis
For the two groups of patients with bladder cancer, the
means and standard deviations for each fatty acid were
calculated. The two groups were then compared using the
Mann-Whitney U-Test. The fatty acids levels in the two
groups, both separately and in combination, were then com-
pared with the normal controls using the unpaired t-test.
Results
Of the 98 patients entered in the study, 55 had active disease
(i.e. recurrence tumour at cystoscopy) and 43 had inactive
disease. The age and sex distribution of the two groups is
outlined in Table I, and shows that the two groups are
comparable by age and sex.
The results of the fatty acid analysis of the plasma phos-
pholipids of the two groups and a control population is
shown in Table II. Comparison of all the cancer patients
with the control population showed significantly lower
plasma levels of the major dietary n-6 EFA, linoleic acid
(P<0.001, t-test), and of all its metabolites except 20:3n6
(dihomogammalinolenic acid) and 22:5n6. The level of the
major dietary n-3 EFA, alpha-linolenic acid, was not
significantly lower than the control level, but the levels of its
metabolites were significantly lower (P<0.001, t-test).
No significant differences were found, using the Mann-
Whitney U-Test, between the active and inactive disease
groups.
Discussion
We have demonstrated significant differences in the plasma
phospholipid profiles of patients with histologically proven
bladder cancer, when compared to a control population.
There were, however, no significant differences between those
patients with active bladder disease and those with inactive
disease. Measurement of the essential fatty acids in the
plasma phospholipids of patients with bladder cancer is not,
therefore, a useful marker of disease activity.
Changes in the plasma levels of the essential fatty acids in
patients with cancer may be related to a pathological metab-
olism and incorporation into phospholipids of the various
fatty acids. Similar variations have been demonstrated in
patients with atopic eczema (Manku et al., 1984), premen-
strual syndrome (Brush et al., 1984) and those at risk of
developing coronary heart disease (Miettinen et al., 1982).
It is possible that in patients with cancer, the cancer itself
may be responsible for changes in essential fatty acid metab-
olism. Tumour cells tend to have a decreased activity of the
desaturase enzymes, particularly the delta-6-desaturase (Reitz
et al., 1977; Bailey, 1977; Horrobin, 1980). This is in keeping
with the known enzymatic differences between cancer cells
and normal control cells, such as changes in enzymatic
activity, concentration and composition (Weber, 1977; Pret-
low et al., 1985). This difference in activity of the tumour cell
delta-6-desaturase leads to lower levels of the fatty acid
derivatives in tumour cells. This seems to be mirrored in the
plasma levels of the fatty acids, perhaps reflecting the diverse
metabolic effects caused by the presence of a tumour. On the
other hand, the lack of any difference between the active and
inactive patients in our study may indicate that the presence
of active tumour has no effect on systemic essential fatty acid
metabolism.
An alternative equally interesting possibility is that the
fatty acid abnormalities may in some way be involved in the
pathogenesis of the tumour. A dietary deficiency of essential
fatty acids does not reliably produce tumours except in the
urinary tract. Rats deprived of dietary essential fatty acids
consistently show pre-malignant and malignant change in the
transitional epithelium of the urinary tract (Monis et al.,
1982). There is thus the possibility that a deficit in essential
fatty acids, as we have shown in our patients, may predispose
to the development of bladder cancer. It is even conceivable
that essential fatty acid supplementation may be of value in
preventing or treating bladder cancer.316 S. McCLINTON et al.
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